Evidence map›Paper›PMID 40242769›Full record

ArticleFrontiers in immunology2025

Angiotensinogen and C3 compete for renin-induced complement activation.

Ann-Charlotte Kristoffersson, Albin Sköld, Charlotte Welinder, Markus Wendler, Gabriella Kalliokoski, Zivile Bekassy, Diana Karpman

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ann-Charlotte KristofferssonDepartment of Pediatrics, Clinical Sciences Lund, Lund University, Lund, Sweden.
Albin SköldDepartment of Pediatrics, Clinical Sciences Lund, Lund University, Lund, Sweden.
Charlotte WelinderMass Spectrometry, Clinical Sciences Lund, Lund University, Lund, Sweden.
Markus WendlerDepartment of Pediatrics, Clinical Sciences Lund, Lund University, Lund, Sweden.
Gabriella KalliokoskiDepartment of Pediatrics, Clinical Sciences Lund, Lund University, Lund, Sweden.
Zivile BekassyDepartment of Pediatrics, Clinical Sciences Lund, Lund University, Lund, Sweden.
Diana KarpmanDepartment of Pediatrics, Clinical Sciences Lund, Lund University, Lund, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renin from plasma, kidney, and recombinant sources was previously demonstrated to cleave C3 to C3a and C3b. C3a was generated at a similar rate to that by C3 convertase, and C3 cleavage was inhibited by the renin inhibitor aliskiren. Renin endogenously produced by Calu6 cells also led to C3 deposition on cells. These results have been challenged by another group suggesting that recombinant renin does not cleave C3 or that renin was contaminated by trypsin, which also cleaves C3. Here, we investigated C3 cleavage by recombinant renin and competitive inhibition in the presence of angiotensinogen. Recombinant renin was analyzed by mass spectrometry using endopeptidase LysC digestion and did not contain trypsin. C3 cleavage, using our protocol and that of the other group, showed cleavage to C3b by immunoblotting. Cleavage was inhibited by aliskiren, which inhibits renin but not trypsin. Cleavage to C3a occurred within 1 min as detected by enzyme-linked immunosorbent assay (ELISA). Angiotensinogen competed for renin-mediated C3 cleavage and inhibited C3a generation, but C3 did not inhibit cleavage of angiotensinogen to angiotensin I (detected by ELISA). The results suggest that renin cleaves C3 but angiotensinogen is its preferred substrate. The interaction between renin and C3 may gain importance in the kidney where renin concentrations are considerably higher than in the circulation and when the primary substrate, angiotensinogen, is cleaved and thereby depleted.

Indexed as

AngiotensinogenComplement ActivationComplement C3ReninRenin InhibitorsAmidesComplement C3aFumaratesHumansRecombinant ProteinsaliskirenAmidesAngiotensinogenComplement C3Complement C3aFumaratesRecombinant ProteinsReninRenin InhibitorsangiotensinogenC3complementkidneyrenin

Identifiers

PMID40242769
PMCPMC11999838

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.